US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jade Biosciences

8.23

+0.850011.52%

Volume:124.81K

Turnover:999.61K

Market Cap:268.52M

PE:-0.44

High:8.30

Open:7.52

Low:7.18

Close:7.38

52wk High:105.00

52wk Low:6.57

Shares:32.63M

Float Shares:16.33M

Volume Ratio:0.78

T/O Rate:0.76%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-18.7916

EPS(LYR):-9.3958

ROE:--

ROA:--

PB:0.09

PE(LYR):-0.88

Loading ...

Overview Company News Filings

Jade Biosciences Inc. to Participate in Cantor Global Healthcare Conference

Wedbush Remains a Buy on Jade Biosciences (JBIO)

Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating

MT Newswires Live

Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate

Jade Biosciences Reports Q2 2025 Net Loss of $32.1M with No Revenue Figures Provided

Jade Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview

institutional investors of Jade Biosciences, Inc. (NASDAQ:JBIO) must be disappointed after last week's 16% drop

Simply Wall St.

Jade Biosciences Inc. Files Initial Beneficial Ownership Statement for CFO Bradford D. Dahms

The early winner in the 'Dexit' war for corporate relocations: Nevada

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer Amid Strategic Growth Initiatives

Jade Biosciences upgraded to Buy from Neutral at Guggenheim

Jade Biosciences presents JADE101 preclinical data at ERA Congress

Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data

Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress

CEO’s Bold Move: Major Stock Purchase at Jade Biosciences

CEO Tom Frohlich Acquires Common Shares of Jade Biosciences Inc

Jade Biosciences Price Target Maintained With a $17.00/Share by Wedbush

Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership

Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/JBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"JBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JBIO\",,,,,undefined,":{"symbol":"JBIO","market":"US","secType":"STK","nameCN":"Jade Biosciences","latestPrice":8.23,"timestamp":1755892800000,"preClose":7.38,"halted":0,"volume":124811,"delay":0,"floatShares":16329500,"shares":32626730,"eps":-18.7916,"marketStatus":"Pre-Mkt","change":0.85,"latestTime":"08-25 08:39:00 EDT","open":7.52,"high":8.3,"low":7.18,"amount":999609.302024,"amplitude":0.151762,"askPrice":9.21,"askSize":100,"bidPrice":6.95,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-18.7916,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1756128600000},"marketStatusCode":1,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":8.23,"postHourTrading":{"tag":"盘后","latestPrice":8.23,"preClose":8.23,"latestTime":"17:53 EDT","volume":4746,"amount":39054.86,"timestamp":1755899630024},"volumeRatio":0.7844370837650801,"impliedVol":0.816,"impliedVolPercentile":0.5606},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"JBIO\",,,,,undefined,":{"symbol":"JBIO","floatShares":16329500,"roa":"--","roe":"--","lyrEps":-9.3958,"volumeRatio":0.7844370837650801,"shares":32626730,"dividePrice":0,"high":8.3,"amplitude":0.151762,"preClose":7.38,"low":7.18,"week52Low":6.565,"pbRate":"0.09","week52High":105,"institutionHeld":0,"latestPrice":8.23,"eps":-18.7916,"divideRate":0,"volume":124811,"delay":0,"ttmEps":-18.7916,"open":7.52,"prevYearClose":92.75,"prevWeekClose":8.23,"prevMonthClose":7.19,"prevQuarterClose":9.99,"fiveDayClose":7.36,"twentyDayClose":8.28,"sixtyDayClose":7.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/JBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-13","symbol":"JBIO","fiscalQuarterEnding":"2025/06","expectedEps":-0.43,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.86},{"date":"2025-04-29","symbol":"JBIO","amount":2.4,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-25","defaultRemindTime":1745933400000,"name":"Jade Biosciences","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-28","payableDate":"2025-04-25","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-04-28"},{"market":"US","date":"2025-04-29","symbol":"JBIO","defaultRemindTime":1745933400000,"type":"split","dateTimestamp":1745899200000,"forFactor":35,"toFactor":1,"ratio":35},{"market":"US","date":"2025-04-25","symbol":"JBIO","fiscalQuarterEnding":"2025/03","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745553600000,"reportTimeType":"post","actualEps":-0.09},{"market":"US","date":"2025-03-27","symbol":"JBIO","fiscalQuarterEnding":"2024/12","expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"JBIO\",market:\"US\",,,undefined,":[{"executeDate":"2025-04-29","recordDate":"2025-04-25","paymentDate":"2025-04-28","value":2.4,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"JBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.2,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1752552000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/JBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"JBIO","date":"2025-08-22","current":-2.56269,"percent":0.535211,"low":-3.822008,"twenty":-3.244933,"median":-2.581542,"eighty":-2.467494,"high":-2.319279,"avg":-2.814374,"sd":0.435503,"marketCap":240785267},"quantilePoints":[{"date":"2025-05-16","current":-2.4743,"twenty":-2.881556,"median":-2.868851,"eighty":-2.514424,"marketCap":232480279},{"date":"2025-05-23","current":-2.511409,"twenty":-2.870857,"median":-2.517932,"eighty":-2.47965,"marketCap":235966978},{"date":"2025-05-30","current":-2.432499,"twenty":-2.695315,"median":-2.507901,"eighty":-2.466944,"marketCap":228552715},{"date":"2025-06-06","current":-2.363881,"twenty":-2.548988,"median":-2.487393,"eighty":-2.464507,"marketCap":222105530},{"date":"2025-06-13","current":-2.381035,"twenty":-2.548988,"median":-2.48419,"eighty":-2.428382,"marketCap":223717326},{"date":"2025-06-20","current":-3.228464,"twenty":-2.618978,"median":-2.48419,"eighty":-2.41603,"marketCap":303340063},{"date":"2025-06-27","current":-3.17357,"twenty":-2.886906,"median":-2.487393,"eighty":-2.426323,"marketCap":298182315},{"date":"2025-07-03","current":-3.822008,"twenty":-3.217485,"median":-2.511409,"eighty":-2.437181,"marketCap":359108215},{"date":"2025-07-11","current":-3.609293,"twenty":-3.553713,"median":-2.554094,"eighty":-2.45809,"marketCap":339121941},{"date":"2025-07-18","current":-3.262773,"twenty":-3.420594,"median":-2.844205,"eighty":-2.467494,"marketCap":306563656},{"date":"2025-07-25","current":-2.857929,"twenty":-3.391775,"median":-2.873866,"eighty":-2.470924,"marketCap":268525263},{"date":"2025-08-01","current":-2.466808,"twenty":-3.382854,"median":-2.844205,"eighty":-2.467494,"marketCap":231776307},{"date":"2025-08-08","current":-2.511409,"twenty":-3.347859,"median":-2.705254,"eighty":-2.467494,"marketCap":235966978},{"date":"2025-08-15","current":-2.350869,"twenty":-3.260028,"median":-2.645214,"eighty":-2.467494,"marketCap":220882962},{"date":"2025-08-22","current":-2.56269,"twenty":-3.244933,"median":-2.581542,"eighty":-2.467494,"marketCap":240785267}],"updateTime":1756093509774},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"JBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562245879","title":"Jade Biosciences Inc. to Participate in Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2562245879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562245879?lang=en_us&edition=fundamental","pubTime":"2025-08-25 19:00","pubTimestamp":1756119610,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc., a biotechnology company specializing in autoimmune disease therapies, is set to participate in the Cantor Global Healthcare Conference on September 3-5, 2025. The company will present a fireside chat on Tuesday, September 3 at 3:20 p.m. ET. A live webcast of this presentation will be available on the Jade Biosciences website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on August 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nNDL98rVdF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4112","JBIO","NDAQ","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4585","BK4539","BK4139"],"gpt_icon":0},{"id":"2559963817","title":"Wedbush Remains a Buy on Jade Biosciences (JBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2559963817","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559963817?lang=en_us&edition=fundamental","pubTime":"2025-08-14 22:45","pubTimestamp":1755182735,"startTime":"0","endTime":"0","summary":"Wedbush analyst Laura Chico maintained a Buy rating on Jade Biosciences today and set a price target of $18.00. The company’s shares opened today a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-jade-biosciences-jbio-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-jade-biosciences-jbio-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","JBIO","BK4539"],"gpt_icon":0},{"id":"2559959764","title":"Wedbush Adjusts Price Target on Jade Biosciences to $18 From $17, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2559959764","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559959764?lang=en_us&edition=fundamental","pubTime":"2025-08-14 19:04","pubTimestamp":1755169460,"startTime":"0","endTime":"0","summary":"Jade Biosciences (JBIO) has an average rating of buy and mean price target of $16.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JBIO"],"gpt_icon":0},{"id":"2559897389","title":"Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559897389","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559897389?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:15","pubTimestamp":1755116153,"startTime":"0","endTime":"0","summary":"Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47106506/jade-biosciences-q2-eps-0-86-misses-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Jade Biosciences Q2 EPS $(0.86) Misses $(0.36) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2559890449","title":"Jade Biosciences Reports Q2 2025 Net Loss of $32.1M with No Revenue Figures Provided","url":"https://stock-news.laohu8.com/highlight/detail?id=2559890449","media":"Reuters","labels":["event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559890449?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:09","pubTimestamp":1755115791,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on August 13, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL6bczXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","NDAQ"],"gpt_icon":0},{"id":"2557522326","title":"Jade Biosciences Inc  expected to post a loss of 43 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557522326","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557522326?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:46","pubTimestamp":1754657181,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc  expected to post a loss of43cents a share - Earnings Preview Jade Biosciences Inc JBIO.OQ JBIO.O is expected to  show no change in quarterly revenue when it reports  results on A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U01ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2555291980","title":"institutional investors of Jade Biosciences, Inc. (NASDAQ:JBIO) must be disappointed after last week's 16% drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2555291980","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555291980?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:39","pubTimestamp":1753875562,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Jade Biosciences implies that they have significant influence over...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-jbio/jade-biosciences/news/institutional-investors-of-jade-biosciences-inc-nasdaqjbio-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","IE00BKPKM429.USD","USJW.SI","QLD","BK4112","PSQ","LU2210150020.SGD","BK4588","BK4585","NQmain","BK4139","SQQQ","USAW.SI","JBIO","QID","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","NVIW.SI","LU2210149790.SGD","LU2095319765.USD","TQQQ","BK4539","MNQmain","IE00B64PRP62.GBP","TSYW.SI"],"gpt_icon":1},{"id":"2551013990","title":"Jade Biosciences Inc. Files Initial Beneficial Ownership Statement for CFO Bradford D. Dahms","url":"https://stock-news.laohu8.com/highlight/detail?id=2551013990","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551013990?lang=en_us&edition=fundamental","pubTime":"2025-07-15 07:11","pubTimestamp":1752534685,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc. has filed an initial statement of beneficial ownership, identifying Bradford D. Dahms as the beneficial owner in his role as Chief Financial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL1dBXnp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4539","BK4139"],"gpt_icon":0},{"id":"2550966255","title":"The early winner in the 'Dexit' war for corporate relocations: Nevada","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966255","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550966255?lang=en_us&edition=fundamental","pubTime":"2025-07-10 16:00","pubTimestamp":1752134415,"startTime":"0","endTime":"0","summary":"More companies are following the example of Tesla's  Elon Musk and signing off on an exit from Delaware.But many are choosing Nevada — not Texas, as Musk did with Tesla in 2024 — as a new corporate home in 2025.The latest example came Wednesday when a high-profile venture capital firm, Andreessen Horowitz, announced it would move the incorporation of its primary business, AH Capital Management, from Delaware to Nevada as it offered a critique of Delaware's powerful business court.The VC firm long associated with Marc Andreessen accused the state's Chancery Court of injecting \"legal uncertainty\" into Delaware's reputation as the gold standard for corporate law.\"In contrast, Nevada has taken significant steps in establishing a technical, non-ideological forum for resolving business disputes,\" the company said.SANTA MONICA, CALIFORNIA - APRIL 05: Marc Andreessen and Laura Arrillaga-Andreessen attend the 2025 Breakthrough Prize Ceremony at Barker Hangar on April 05, 2025 in Santa Monica, C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/the-early-winner-in-the-dexit-war-for-corporate-relocations-nevada-080015108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJLML261.HKD","XOMA","LU2087621335.USD","DXYZ","ULH","BK4565","LU1861558580.USD","DBX","LU0082616367.USD","LU0719512351.SGD","TSYW.SI","GXAI","IE00BSNM7G36.USD","BK4528","LU0689472784.USD","BK4585","BK4533","BK4108","BK4574","AMCX","LU0316494557.USD","LU0820562030.AUD","BK4099","TEM","OCTO","LU1861220033.SGD","SNOA","LU0348723411.USD","LU1720051017.SGD","MARK","LU2326559502.SGD","SPHR","LU0823414478.USD","LU0957808578.USD","LU1066053197.SGD","LU2750360641.GBP","IE00BK4W5M84.HKD","REVB","TTD","BK4555","BK4592","FNF","BK4611","SG9999015952.SGD","SG9999001440.SGD","LU1674673428.USD","RBLX","JBIO","LU1852331112.SGD"],"gpt_icon":1},{"id":"2549185549","title":"Jade Biosciences to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2549185549","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549185549?lang=en_us&edition=fundamental","pubTime":"2025-07-08 19:00","pubTimestamp":1751972400,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and VANCOUVER, British Columbia, July  08, 2025  (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapie","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/08/3111586/0/en/Jade-Biosciences-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4139","BK4539"],"gpt_icon":0},{"id":"2548003512","title":"Jade Biosciences Appoints Brad Dahms as Chief Financial Officer Amid Strategic Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2548003512","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548003512?lang=en_us&edition=fundamental","pubTime":"2025-07-01 19:00","pubTimestamp":1751367617,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc., a biotechnology company focused on therapies for autoimmune diseases, has appointed Brad Dahms as its new Chief Financial Officer. Dahms brings extensive experience in corporate strategy, business development, and capital markets, having previously held CFO positions at IDRx and Theseus Pharmaceuticals. His appointment follows Jade Biosciences' recent Nasdaq listing and private financing, as the company advances its lead candidate JADE101 into clinical trials for IgA nephropathy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on July 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nNDL6fy36S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4139","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4588","LU2210150020.SGD","JBIO","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4539","IE00B64PRP62.GBP","NDAQ","BK4585"],"gpt_icon":0},{"id":"2543612021","title":"Jade Biosciences upgraded to Buy from Neutral at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2543612021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543612021?lang=en_us&edition=fundamental","pubTime":"2025-06-16 08:20","pubTimestamp":1750033209,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Vamil Divan upgraded Jade Biosciences (JBIO) to Buy from Neutral with a $14 price target Published first on TheFly – the ultimat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jade-biosciences-upgraded-to-buy-from-neutral-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jade-biosciences-upgraded-to-buy-from-neutral-at-guggenheim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JBIO"],"gpt_icon":0},{"id":"2542389101","title":"Jade Biosciences presents JADE101 preclinical data at ERA Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2542389101","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542389101?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:10","pubTimestamp":1749467433,"startTime":"0","endTime":"0","summary":"Jade Biosciences (JBIO) announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand monoclonal antibody,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jade-biosciences-presents-jade101-preclinical-data-at-era-congress-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jade-biosciences-presents-jade101-preclinical-data-at-era-congress-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","JBIO"],"gpt_icon":0},{"id":"2542408386","title":"Jade Biosciences Announces Upcoming Clinical Trial for JADE101 in IgA Nephropathy Following Promising Preclinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2542408386","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542408386?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:00","pubTimestamp":1749466838,"startTime":"0","endTime":"0","summary":"Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy . Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDLWc4xq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4585","LU2210150020.SGD","BK4139","BK4588","JBIO","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4539"],"gpt_icon":0},{"id":"2540762701","title":"Jade Biosciences Announces New Preclinical Data on JADE101 for IgA Nephropathy at 62nd ERA Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2540762701","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540762701?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:00","pubTimestamp":1748862040,"startTime":"0","endTime":"0","summary":"Jade Biosciences, Inc., a biotechnology company specializing in autoimmune disease therapies, announced the presentation of new preclinical data on its anti-APRIL monoclonal antibody, JADE101, at the 62nd European Renal Association Congress. The data, aimed at treating IgA nephropathy , will be shared during a Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases in Vienna on June 6, 2025. The presentation, led by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences, will focus on the discovery and characterization of JADE101. Following the congress, Jade Biosciences plans to host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the findings. Investors and the public can register for the event on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL25JFkg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","JBIO","LU2095319765.USD","IE00BKPKM429.USD","BK4112","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4539","BK4588"],"gpt_icon":0},{"id":"2536047650","title":"CEO’s Bold Move: Major Stock Purchase at Jade Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2536047650","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536047650?lang=en_us&edition=fundamental","pubTime":"2025-05-20 10:12","pubTimestamp":1747707134,"startTime":"0","endTime":"0","summary":"New insider activity at Jade Biosciences ( ($JBIO) ) has taken place on May 20, 2025. Chief Executive Officer Tom Frohlich has made a significant i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/ceos-bold-move-major-stock-purchase-at-jade-biosciences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/ceos-bold-move-major-stock-purchase-at-jade-biosciences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","JBIO"],"gpt_icon":0},{"id":"2536460630","title":"CEO Tom Frohlich Acquires Common Shares of Jade Biosciences Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2536460630","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536460630?lang=en_us&edition=fundamental","pubTime":"2025-05-20 04:54","pubTimestamp":1747688085,"startTime":"0","endTime":"0","summary":"Tom Frohlich, the Chief Executive Officer and Director of Jade Biosciences Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jade Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nNDL5hg8VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4539","BK4139"],"gpt_icon":0},{"id":"2535827408","title":"Jade Biosciences Price Target Maintained With a $17.00/Share by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2535827408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535827408?lang=en_us&edition=fundamental","pubTime":"2025-05-15 23:08","pubTimestamp":1747321680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/JBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 11:08 ET (15:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0},{"id":"2535488146","title":"Promising Future for Jade Biosciences: Buy Rating Backed by Innovative JADE101 and Experienced Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2535488146","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535488146?lang=en_us&edition=fundamental","pubTime":"2025-05-15 06:45","pubTimestamp":1747262711,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on JBIO stock, giving a Buy rating on May 7. Tyler Van Buren has given his Buy...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-future-for-jade-biosciences-buy-rating-backed-by-innovative-jade101-and-experienced-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-future-for-jade-biosciences-buy-rating-backed-by-innovative-jade101-and-experienced-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JBIO"],"gpt_icon":0},{"id":"2535000700","title":"Jade Biosciences Q1 EPS $(12.10) Misses $(1.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000700","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000700?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:42","pubTimestamp":1747255376,"startTime":"0","endTime":"0","summary":"Jade Biosciences (NASDAQ:JBIO) reported quarterly losses of $(12.10) per share which missed the analyst consensus estimate of $(1.74) by 595.4 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45421947/jade-biosciences-q1-eps-12-10-misses-1-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}